New hope for Hard-to-Treat breast cancer: experimental drug ARV-471 shows promise
NCT ID NCT04072952
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests an experimental drug called ARV-471, alone or with another drug (palbociclib), in 217 people with advanced ER+/HER2- breast cancer that has stopped responding to standard treatments. The goal is to see if it is safe and can shrink tumors or slow the disease. The study is completed, but results are not yet widely available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ARV-471 (a drug that breaks down estrogen receptors) and palbociclib (a targeted cancer drug)
What this could lead to
If it works, this could offer a new treatment option for people with advanced ER+/HER2- breast cancer who have run out of standard therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so safety and effectiveness are not yet proven. Side effects or lack of benefit could limit its use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trial Site
Palo Alto, California, 94304, United States
-
Clinical Trial Site
San Francisco, California, 94158, United States
-
Clinical Trial Site
Santa Monica, California, 90404, United States
-
Clinical Trial Site
Norwalk, Connecticut, 06856, United States
-
Clinical Trial Site
Fort Myers, Florida, 33901, United States
-
Clinical Trial Site
Tampa, Florida, 33612, United States
-
Clinical Trial Site
Chicago, Illinois, 60637, United States
-
Clinical Trial Site
Boston, Massachusetts, 02114, United States
-
Clinical Trial Site
Boston, Massachusetts, 02215, United States
-
Clinical Trial Site
Ann Arbor, Michigan, 48109, United States
-
Clinical Trial Site
St Louis, Missouri, 63110, United States
-
Clinical Trial Site
East Brunswick, New Jersey, 08816, United States
-
Clinical Trial Site
The Bronx, New York, 10461, United States
-
Clinical Trial Site
Charlotte, North Carolina, 28204, United States
-
Clinical Trial Site
Nashville, Tennessee, 37203, United States
-
Clinical Trial Site
Seattle, Washington, 98109, United States